Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nausea Clear all
Completed Not applicable Interventional Results available

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

NCT02625181
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
Procedure · Device · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection

NCT00273377
View directory record Official record
Conditions
Surgical Wound Infection, Surgery, Colon
Interventions
Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg), Supplemental oxygen (80% vs. 30%), Dexamethasone, Placebo
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

NCT01534637
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
Drug · Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Not applicable Interventional

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254
View directory record Official record
Conditions
Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting
Interventions
Domperidone
Drug
Lead sponsor
Carle Physician Group
Individual
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 20, 2026, 10:12 PM EDT
Not listed Phase 2 Interventional

Intravenous Acetaminophen for Craniotomy Patients

NCT01474304
View directory record Official record
Conditions
Craniotomy
Interventions
Acetaminophen
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

NCT00489255
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tigan®, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional

12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting

NCT00252993
View directory record Official record
Conditions
Vomiting
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Mobile, Alabama • Scottsdale, Arizona • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2007 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Biomagnetic Characterization of Gastric Dysrhythmias III

NCT03176927
View directory record Official record
Conditions
Diabetics Without Symptoms of Gastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis, Total or Partial Gastrectomy, Chronic Nausea, Functional Dyspepsia
Interventions
magnetogastrogram
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
aprepitant, ondansetron, dexamethasone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

NCT00553059
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dexamethasone, dronabinol, palonosetron hydrochloride, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Springfield, Missouri • Greenville, South Carolina • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

NCT01499849
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

NCT00748267
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Nausea and Vomiting, Pain
Interventions
questionnaire administration, hypnotherapy, therapeutic conventional surgery
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 20, 2026, 10:12 PM EDT
Enrolling by invitation No phase listed Observational

Impact of Aromatherapy on Nausea in Hospitalized Children Undergoing Rehabilitation

NCT06009211
View directory record Official record
Conditions
Nausea
Interventions
QueaseEase
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum

NCT02163434
View directory record Official record
Conditions
Hyperemesis Gravidarum
Interventions
Gabapentin, Metoclopramide
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

NCT00460707
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Overland Park, Kansas • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Completed No phase listed Observational

Cardiac Vagal Effects of GES in Patients With Gastroparesis and Vagal Nerve Action Potentials in Vagus Nerve

NCT02159586
View directory record Official record
Conditions
Gastroparesis
Interventions
gastric electrical stimulator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 90 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 20, 2026, 10:12 PM EDT
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

NCT00326248
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
GW679769 (casopitant)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
26
States / cities
Montgomery, Alabama • Sheffield, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional

Effect of TEAS on PONV After Spinal Surgery

NCT03187535
View directory record Official record
Conditions
PONV
Interventions
TEAS via ES-130, No TEAS
Device · Other
Lead sponsor
Jyoti Pandya
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

NCT01649258
View directory record Official record
Conditions
Breast Cancer, Nausea, Vomiting
Interventions
granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT01432015
View directory record Official record
Conditions
Ovarian Cancer, Uterine Cancer
Interventions
fosaprepitant, aprepitant, Oral Placebo, IV placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 20, 2026, 10:12 PM EDT